AOC 1020
Facioscapulohumeral Muscular Dystrophy (FSHD)
Key Facts
Indication
Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase
Phase 1/2
Status
Active
Company
About Avidity Biosciences
Avidity Biosciences is a clinical-stage biotech with a mission to profoundly improve lives by delivering a new class of targeted RNA therapeutics. Its core innovation is the AOC platform, which overcomes the historic delivery barriers of oligonucleotide therapies by using antibodies as tissue-specific delivery vehicles. The company is executing a focused strategy, advancing a pipeline of AOCs for rare muscle diseases with high unmet need, aiming to establish clinical proof-of-concept that can unlock the platform's potential across a broad range of therapeutic areas. Recent clinical data readouts have generated significant investor confidence, reflected in its multi-billion dollar valuation.
View full company profileTherapeutic Areas
Other Facioscapulohumeral Muscular Dystrophy (FSHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DX5057 | Altay Therapeutics | Preclinical |
| Restem-L | Restem | Unknown |
| DYNE-301 | Dyne Therapeutics | Phase 1/2 |
| Losmapimod | Fulcrum Therapeutics | Phase 3 |